2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Dihydroorotate Dehydrogenase

Dihydroorotate Dehydrogenase

DHODH

Dihydroorotate Dehydrogenase

Related Products

PDF 0.6 MB

Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). DHODH is a known target for autoimmune diseases as well as an important target for malaria.

Based on localization and electron acceptor, DHODHs have classified into two families: Family 1 members are soluble proteins localized to the cytosol, while family 2 members are membrane proteins localized to the inner mitochondrial membrane. Family 1 is further subdivided into family 1A and family 1B, which use fumarate and NAD+ (respectively) as electron acceptors. Family 2 DHODH enzymes use respiratory quinones as electron acceptors.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158023
    DHODH-IN-26
    		Inhibitor
    DHODH-IN-26 (compound B2) is a mitochondria-targeting DHODH inhibitor. DHODH-IN-26 shows anticancer activity, triggers the formation of reactive oxygen species (ROS), promots mitochondrial lipid peroxidation, and induces ferroptosis.
    DHODH-IN-26
  • HY-135679
    DHODH-IN-15
    		Inhibitor
    DHODH-IN-15 (Compound 7b) is a hydroxyfurazan analog of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis.
    DHODH-IN-15
  • HY-139825
    Indoluidin E
    		Inhibitor
    Indoluidin E selectively inhibits DHODH and suppresses cancer cell growth.
    Indoluidin E
  • HY-163328
    DHODH-IN-25
    		Inhibitor
    DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML).
    DHODH-IN-25
  • HY-135619
    DHODH-IN-4
    		Inhibitor
    DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor, with IC50 values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity.
    DHODH-IN-4
  • HY-N6961R
    Lapachol (Standard)
    		Inhibitor
    Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity.
    Lapachol (Standard)
  • HY-147788
    hDHODH-IN-9
    		Inhibitor
    hDHODH-IN-9 (Compound 3k) is a potent inhibitor of hDHODH with an IC50 of 0.34 μM. hDHODH-IN-9 demonstrates high cytotoxic activity against MCF-7 and A375 cells and good selectivity. hDHODH-IN-9 has the potential for the research of cancer diseases.
    hDHODH-IN-9
  • HY-163158
    DHODH-IN-24
    		Inhibitor
    DHODH-IN-24 (compound 16) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 91 nM.
    DHODH-IN-24
  • HY-146317
    P1788
    		Inhibitor
    P1788 is a dihydroorotate dehydrogenase (DHODH) inhibitor. P1788 induces DNA damage.
    P1788
  • HY-B0083R
    Leflunomide (Standard)
    		Inhibitor
    Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
    Leflunomide (Standard)
  • HY-120462
    Genz-669178
    		Inhibitor
    Genz-669178 is an inhibitor for dihydroorotate dehydrogenase (DHODH) with IC50 of 0.015-0.05 μM in Plasmodium spp.. Genz-669178 inhibits P. berghei, P. falciparum strains 3D7 and Dd2 with IC50 of 0.068, 0.008 and 0.01 μM, respectively. Genz-669178 exhibits anti-malarial efficacy in P. berghei-infected mice with ED50 of 13-21 mg/kg/day. Genz-669178 exhibits good pharmacokinetic characteristics in mice.
    Genz-669178
  • HY-169220S
    RORγ/DHODH-IN-1
    		Inhibitor
    RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC50 values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5).
    RORγ/DHODH-IN-1
  • HY-114215
    DSM-421
    		Inhibitor
    DSM-421 is an orally active Dihydroorotate dehydrogenase inhibitor. DSM-421 has antiplasmodium activity.
    DSM-421
  • HY-169222S
    RORγ/DHODH-IN-2
    		Inhibitor
    RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively.
    RORγ/DHODH-IN-2
  • HY-116736
    BRD7539
    		Inhibitor
    BRD7539 is a PfDHODH inhibitor (IC50 = 0.033 μM). BRD7539 has potent activity against both multidrug-resistant asexual blood-stage (P. falciparum, Dd2 strain, EC50 = 0.010 μM) and liver-stage (P. berghei, EC50 = 0.015 μM) parasites.
    BRD7539
Cat. No. Product Name / Synonyms Application Reactivity